Neil D. Gross, MD, FACS

Articles

Optimizing Multidisciplinary Collaboration in cSCC Care

November 11th 2025

Panelists discuss strategies for integrating dermatology, surgery, radiation, and oncology to deliver cohesive, patient-centered cSCC care.

Long-Term Follow-Up and Surveillance After Adjuvant Therapy

November 11th 2025

Panelists discuss strategies for long-term surveillance and management of patients with cSCC who have received adjuvant immunotherapy.

Clinical Trial Design and Outcomes in Adjuvant Immunotherapy for cSCC

November 11th 2025

Panelists discuss ongoing clinical trials evaluating adjuvant immunotherapy for cSCC and the implications of early outcomes for clinical practice.

Selecting Candidates for Adjuvant Immunotherapy in cSCC

November 11th 2025

Panelists discuss how clinicians identify which patients are most likely to benefit from adjuvant immunotherapy based on clinical and pathologic risk factors.

The Evolving Role of Adjuvant Immunotherapy

November 10th 2025

Panelists discuss ongoing clinical trials, including adjuvant immunotherapy studies, and identify which patients are most likely to benefit from these strategies.

Integrating Systemic Therapy Into cSCC Management

November 10th 2025

Panelists discuss the growing use of systemic immunotherapy for advanced or unresectable cSCC and how it integrates with other modalities.

Role of Radiotherapy in Managing cSCC

November 10th 2025

Panelists discuss when radiation therapy is appropriate for treating cSCC, and how it complements surgical management.

Identifying Surgical Candidates in cSCC

November 10th 2025

Panelists discuss how to identify appropriate surgical candidates and coordinate timely referral to specialized surgical teams.

Defining Primary Treatment Options in cSCC

November 10th 2025

Panelists discuss standard primary treatment modalities for cSCC, emphasizing surgical control and selective use of adjunctive therapy.

Recognizing High-Risk cSCC Patients for Early Biopsy

November 10th 2025

Panelists discuss patient populations requiring earlier biopsy and aggressive workup to detect high-risk cSCC.

Applying Guideline-Based Care Pathways in cSCC

November 10th 2025

Panelists discuss the importance of following evidence-based clinical pathways and national guidelines to streamline cSCC care.

Balancing In-Clinic Treatment and Referral in cSCC

November 10th 2025

Panelists discuss when cSCC can be managed within dermatology and when multidisciplinary referral is warranted.

Dermatology’s Role in Diagnosing and Managing cSCC

November 10th 2025

Panelists discuss how dermatologists serve as the first line of detection and play an essential role in early management and triage of cSCC.

Approach to Evaluating Suspected cSCC

November 10th 2025

Panelists discuss best practices for evaluating suspected cSCC, including lesion assessment, biopsy strategies, and initial patient workup.

Assessing Risk in cSCC: Key Clinical and Pathologic Markers

November 10th 2025

Panelists discuss clinical and pathological factors used to stratify cSCC into low-, high-, and very high-risk categories.

Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC

June 27th 2024

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab in the treatment of patients with cutaneous squamous cell carcinoma.

Dr Gross on the Safety of Neoadjuvant Cemiplimab in Stage II/IV CSCC

March 5th 2024

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr Gross on the Background of Investigating Neoadjuvant Cemiplimab in CSCC

February 23rd 2024

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr Gross on Updated Survival Outcomes With Neoadjuvant Cemiplimab in CSCC

October 27th 2023

Neil D. Gross, MD, FACS, discusses 1-year follow-up data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr. Gross on the Investigation of Cemiplimab in Cutaneous Squamous Cell Carcinoma

October 20th 2022

Neil D. Gross, MD, FACS, discusses the investigation of cemiplimab in cutaneous squamous cell carcinoma.